During the development of antitumor CD8 + T cell exhaustion, several key genes predominate; these genes may serve as targets for immunotherapies or as prognostic biomarkers for HCC patients [17, 25, 26]. The gene discussed is CD8A; the disease is hepatocellular carcinoma.